| Symbol | BYSI |
|---|---|
| Name | BEYONDSPRING INC. |
| Sector | UNDEFINED |
| Region | UNDEFINED |
| Industry | Pharmaceutical Preparations |
| Address | 100 CAMPUS DRIVE, WEST SIDE, 4TH FLOOR, FLORHAM PARK, NJ 07932 |
| Telephone | 646-528-4184 |
| Fax | — |
| — | |
| Website | — |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001677940 |
| Description | None |
Majeti Jiangwen 🟢 acquired 100.0K shares (1 derivative) of BeyondSpring Inc. (BYSI) at $1.75 Transaction Date: Jul 01, 2026 | Filing ID: 295935
Read moreQiu Min 🟢 acquired 100.0K shares (1 derivative) of BeyondSpring Inc. (BYSI) at $1.75 Transaction Date: Jul 01, 2026 | Filing ID: 295934
Read moreNew Form 3 - BeyondSpring Inc. <b>Filed:</b> 2026-07-06 <b>AccNo:</b> 0001193125-26-295932 <b>Size:</b> 3 KB
Read moreNew Form 3 - BeyondSpring Inc. <b>Filed:</b> 2026-07-06 <b>AccNo:</b> 0001193125-26-295930 <b>Size:</b> 3 KB
Read more(19% Negative) BEYONDSPRING INC. (BYSI) Announces Clinical Trial Timeline Adjustment
Read moreBeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value
Read moreBeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026
Read moreNew Form SCHEDULE 13G/A - BeyondSpring Inc. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001140361-26-021645 <b>Size:</b> 19 KB
Read more(10% Negative) BEYONDSPRING INC. (BYSI) Reports Q2 2026 Financial Results
Read more